Clinical Trial Update: TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer [Phase 3]

View source ↗

Summary

This is a completed Phase 3 trial comparing TLK286 (Telcyta) to Doxil/Caelyx or Hycamtin in platinum-refractory or resistant ovarian cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Hycamtin (Topotecan)
• Telcyta (TLK286)

Snippet

Sponsor: Telik | Conditions: Ovarian Neoplasms | Phase 3 | Status: COMPLETED